Register to view the archived recording here.
Alnylam Joins Max Planck in Suit Against Whitehead, UMass, MIT Over Tuschl IP Portfolio
The lawsuit alleges that the defendants have sought to include in their patent applications inventions that belong solely to Max Planck and licensed exclusively to Alnylam. While licenses to the IP have been a big moneymaker for Alnylam, some companies have begun looking to alternative RNAi technologies.
New to GenomeWeb? Register here quickly.